Aquestive Therapeutics Inc (NASDAQ: AQST)’s stock price has decreased by -3.43 compared to its previous closing price of 3.50. However, the company has seen a 0.60% increase in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-05-07 that The headline numbers for Aquestive Therapeutics (AQST) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Is It Worth Investing in Aquestive Therapeutics Inc (NASDAQ: AQST) Right Now?
The stock has a 36-month beta value of 2.85. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AQST is 80.74M, and at present, short sellers hold a 4.96% of that float. On May 08, 2024, the average trading volume of AQST was 2.85M shares.
AQST’s Market Performance
AQST stock saw a decrease of 0.60% in the past week, with a monthly decline of -16.95% and a quarterly a decrease of 21.15%. The volatility ratio for the week is 7.04%, and the volatility levels for the last 30 days are 8.91% for Aquestive Therapeutics Inc (AQST). The simple moving average for the past 20 days is -13.10% for AQST’s stock, with a 34.06% simple moving average for the past 200 days.
Analysts’ Opinion of AQST
Many brokerage firms have already submitted their reports for AQST stocks, with Piper Sandler repeating the rating for AQST by listing it as a “Overweight.” The predicted price for AQST in the upcoming period, according to Piper Sandler is $10 based on the research report published on April 11, 2024 of the current year 2024.
Raymond James, on the other hand, stated in their research note that they expect to see AQST reach a price target of $7. The rating they have provided for AQST stocks is “Outperform” according to the report published on March 28th, 2024.
RBC Capital Mkts gave a rating of “Outperform” to AQST, setting the target price at $7 in the report published on April 07th of the previous year.
AQST Trading at -20.24% from the 50-Day Moving Average
After a stumble in the market that brought AQST to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.75% of loss for the given period.
Volatility was left at 8.91%, however, over the last 30 days, the volatility rate increased by 7.04%, as shares sank -17.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +18.60% upper at present.
During the last 5 trading sessions, AQST rose by +0.60%, which changed the moving average for the period of 200-days by +113.92% in comparison to the 20-day moving average, which settled at $3.85. In addition, Aquestive Therapeutics Inc saw 67.33% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AQST starting from Schobel Alexander Mark, who sale 50,000 shares at the price of $6.00 back on Mar 15 ’24. After this action, Schobel Alexander Mark now owns 984,476 shares of Aquestive Therapeutics Inc, valued at $300,000 using the latest closing price.
Schobel Alexander Mark, the Chief Innovation/Tech Officer of Aquestive Therapeutics Inc, sale 25,000 shares at $5.19 during a trade that took place back on Mar 08 ’24, which means that Schobel Alexander Mark is holding 1,040,371 shares at $129,685 based on the most recent closing price.
Stock Fundamentals for AQST
Current profitability levels for the company are sitting at:
- -0.02 for the present operating margin
- 0.59 for the gross margin
The net margin for Aquestive Therapeutics Inc stands at 0.07. The total capital return value is set at -0.02.
Based on Aquestive Therapeutics Inc (AQST), the company’s capital structure generated -7.15 points at debt to capital in total, while cash flow to debt ratio is standing at -0.07. The debt to equity ratio resting at -0.88. The interest coverage ratio of the stock is -0.19.
Currently, EBITDA for the company is -13.54 million with net debt to EBITDA at 253.21. When we switch over and look at the enterprise to sales, we see a ratio of 7.17. The receivables turnover for the company is 5.97for trailing twelve months and the total asset turnover is 0.88. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.24.
Conclusion
To sum up, Aquestive Therapeutics Inc (AQST) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
